SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amidst heightened geopolitical tensions, primarily fueled by President Trump's recent rhetoric regarding Greenland and threats of substantial tariffs against European allies like France. The community is bracing for significant market volatility, with many predicting a "bloodbath" and actively discussing bearish positions, while others anticipate a "buy the dip" recovery. These concerns are amplified by broader instability in global financial markets, including surging bond yields in both the US and Japan.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid escalating geopolitical tensions and tariff threats from the US concerning Greenland, compounded by an anticipated Supreme Court decision related to tariffs, which has triggered a pre-market sell-off in tech-heavy indices. Community sentiment is sharply divided; while some anticipate a severe market downturn and "Black Tuesday," many others see this as a manufactured dip and a "buy the dip" opportunity, expecting a quick recovery. This dynamic reflects QQQ's sensitivity to global trade policy and broader economic uncertainties, despite ongoing tech sector narratives.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant buzz following its Saudi FDA approval for non-small cell lung cancer, signaling a potential paradigm shift in cancer treatment. The community is fiercely optimistic, citing high short interest, CEO Dr. Patrick Soon-Shiong's vocal advocacy against perceived FDA bureaucracy, and the company's mission to cure cancer as drivers for an anticipated massive short squeeze and substantial growth.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending strongly, fueled by recent breakthrough pancreatic cancer data and high expectations surrounding its J.P. Morgan Healthcare Conference presentation. The community is abuzz with anticipation for imminent PMDA approval in Japan and rumored institutional buying, spotlighting Alpha Tau's innovative Alpha DaRT technology as a potentially undervalued and disruptive force in oncology. Significant trading volume reflects growing investor confidence and a belief that clinical milestones are poised to drive substantial upside, independent of broader market trends.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is heavily discussed due to its strong pivot towards becoming a major AI cloud infrastructure provider, significantly highlighted by a massive power and infrastructure deal with a prominent tech client. Community sentiment points to high expectations for additional large-scale AI/HPC partnerships, particularly given its substantial power capacity and strategic advantages in the booming compute sector. Investors are actively watching for further developments as the company solidifies its position beyond traditional crypto mining.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as investors are enthusiastic about recent confirmations of its Optical Interposer technology being utilized by major players like Marvell, acquired through Celestial AI. The community is actively discussing POET's role as a critical enabler for the AI and data center "optical supercycle" by offering high-density, low-power, and cost-effective optical interconnect solutions. Anticipation is high for upcoming customer and investor disclosures, though some perceive market manipulation hindering immediate price appreciation.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is experiencing significant upward momentum driven by strong preliminary Q4 results and an accelerated 2026 outlook, with IBSRELA revenue now projected to reach $1 billion by 2029. This bullish sentiment is further fueled by a patent extension for both IBSRELA and XPHOZAH until 2041, which the community sees as a 'game changer' fundamentally re-rating the company's long-term value and sparking widespread speculation about potential acquisition interest.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending due to its strategic joint venture for a rare earth processing facility with a major Saudi industrial conglomerate, aiming to secure a mine-to-processing supply chain. The community is actively discussing the geopolitical implications of Greenland's critical mineral assets, viewing CRML as pivotal to Western rare earth independence. This positions the company as a key player in essential resource security, fueling widespread anticipation for future developments.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending amidst a notable downturn, with community discussion centered on a resurfaced short report alleging fraudulent data practices and money laundering. Despite recent analyst upgrades highlighting its strong fundamentals and AI-driven ad platform, many investors are debating whether the sharp decline stems from market manipulation or presents a strategic buying opportunity ahead of upcoming earnings.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is trending following its Investor Day, where the company announced significantly raised revenue guidance for 2026 and a substantial increase in its backlog, alongside a billion-dollar offering that reflects strong institutional confidence in its strategic defense technology acquisitions. The community is sharply divided, with bulls emphasizing the firm's combat-proven drone and counter-UAS capabilities for future growth, while others express concern over stock volatility and valuation, leading to a mixed market reaction to its updated outlook.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Cara Therapeutics, Inc. (CARA) traded 10% higher on Monday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announces-1-3-reverse-stock-split-connection">announced</a> that its board of directors has approved a 1-for-3 reverse stock split of its outstanding shares of common stock.Cara’s common stock is expected to begin trading on a reverse stock split adjusted basis at the opening bell on Wednesday.The company’s common stock will trade under the new name “Tvardi Therapeutics, Inc.” and under the new symbol “TVRD” upon the closing of its merger with privately held, clinical-stage, biopharmaceutical company Tvardi Therapeutics, Inc, the company said.The two companies announced a merger in December. As per the agreement, Cara Therapeutics stockholders are expected to own about 17% of the combined company, and pre-merger Tvardi Therapeutics investors are expected to own approximately 83% of the combined company.On Tuesday evening, every three issued and outstanding shares of Cara’s common stock will automatically be combined into one, effectively reducing the number of issued and outstanding shares of the company's common stock from about 4.6 million to 1.5 million.The company said that fractional shares will not be issued as part of the reverse stock split; instead, entitled shareholders will receive a cash payment.Cara said that after the merger closes, the combined company's total outstanding common stock is expected to be approximately 9.4 million shares.On Stocktwits, retail sentiment around Cara jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours while message volume rose from ‘extremely low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:648/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_1_24_29_PM_png_3d87e8bbd9.webp" alt="CARA's Sentiment Meter and Message Volume as of 1:25 p.m. ET on April 14, 2025 | Source: Stocktwits" width="648" height="153"><figcaption>CARA's Sentiment Meter and Message Volume as of 1:25 p.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CARA">CARA stock</a> is up by about 1% year-to-date but down by about 37% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ny-fed-survey-of-consumer-expectations/chfCQEoRbaa">NY Fed Survey Of Consumer Expectations Shows Short-Term Inflation Expectations Rose, Unemployment Worries Hit COVID-19 Levels</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars

On Tuesday evening, every three issued and outstanding shares of CARA’s common stock will automatically be combined into one, effectively reducing the number of issued and outstanding shares of the company's common stock from about 4.6m to 1.5m.

Equity

On Tuesday evening, every three issued and outstanding shares of CARA’s common stock will automatically be combined into one, effectively reducing the number of issued and outstanding shares of the company's common stock from about 4.6 million to 1.5 million.

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. The company was founded in 2017 and is headquartered in Sugar Land, TX.

Current Price	$4.57
Prev Close	$4.51
Open	$4.63
Dividend Yield	0.00%
50-Day Moving Average	$4.15
Beta	-0.16
Avg. Volume	136,902.23
PE Ratio	-0.46

52-Week High	$43.65
52-Week Low	$3.74
Market Capitalization	$42.87M
EPS (Annual)	-$46.60
Price to Book	1.54
Revenue Per Employee	$713,700.00
Enterprise Value/EBITDA	N/A

CARA
Cara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CARA News

CARACara Therapeutics Inc